Title

篩選可刺激類升糖素胜肽-1分泌之益生菌及探討其減緩高血糖症之研究

Translated Titles

Selecting of probiotics with GLP-1 enhancing ability to attenuate hyperglycemia in vitro and in vivo

Authors

魏士弘

Key Words

益生菌 ; 類升糖素胜肽-1 ; 高血糖 ; 糖尿病 ; Probiotic ; Glucagon-like peptide-1 ; Hyperglycemia ; Diabetes

PublicationName

臺灣大學動物科學技術學研究所學位論文

Volume or Term/Year and Month of Publication

2014年

Academic Degree Category

碩士

Advisor

陳明汝

Content Language

繁體中文

Chinese Abstract

第一型糖尿病(type 1 diabetes, T1D)是一種自體免疫疾病,由於胰臟中β細胞逐漸失去功能並死亡,導致胰島素分泌不足及高血糖症狀。類升糖素胜肽-1(glucagon-like peptide-1, GLP-1)是由腸道內泌細胞所分泌之腸泌素,可調節胰臟β細胞之生長、增加胰島素分泌量以調節血糖之恆定。因此本試驗旨在篩選可刺激腸道內泌細胞分泌GLP-1之乳酸菌株。 試驗選用六十株乳酸菌分別與上皮內泌細胞株STC-1以1:100之比例共培養,測定上清液中之GLP-1濃度,並挑選與對照組相比可顯著提高GLP-1分泌量(p< 0.05)之兩株乳酸菌進行定序,分別為Lactobacillus kefiranofaciens 與 Lactobacillus kefiri。為進一步探討此二篩選菌株於動物模型中是否具有刺激GLP-1分泌能力及調節血糖之機能性,動物試驗選用4週齡C57BL/6小鼠進行試驗,以每公斤體重40 mg之鏈脲佐菌素連續腹腔注射4天以誘導T1D,成功誘導T1D之小鼠隨機分組,分別給予磷酸緩衝液之對照組,及每天每隻小鼠給予108 CFU之篩選菌株,一共8週。結果顯示,Lb. kefiranofaciens 與 Lb. kefiri皆能顯著降低T1D小鼠之空腹血糖值,而Lb. kefiri組別經口服糖耐量測定後也顯著改善了小鼠恆定血糖能力。藉由胰臟切片之免疫組織化學染色發現給予Lb. kefiranofaciens 與 Lb. kefiri後,胰臟β細胞對胰島之面積比例顯著高於STZ對照組,同時也觀察到篩選菌株具有調節細胞激素含量及提高血清GLP-1含量之能力。然而在非肥胖糖尿病(non obese diabetes, NOD)小鼠試驗中,給予Lb. kefiri無法顯著預防T1D之發生。本試驗嘗試探討篩選菌株降血糖功效之可能機制,然而結果顯示其降血糖功效似乎與類鐸受體2(Toll-like receptor 2)之訊息傳遞及短鏈脂肪酸(short chain fatty acid)之含量並無關聯。 綜觀上述,本試驗篩選之乳酸菌株Lb. kefiranofaciens與Lb. kefiri於體外試驗及動物試驗皆能刺激GLP-1分泌,且有助於STZ誘導T1D小鼠維持血糖恆定,此二篩選菌株或許具有高度潛力可開發成為具降血糖機能性之益生菌產品,並應用於糖尿病之輔助療法之一。然而其詳細降血糖機制仍有待釐清。

English Abstract

Type 1 diabetes (T1D) is an autoimmune disease, which characterized by progressive dysfunction of pancreatic β cell and loss in β cell mass. The disease generally results in insulin deficiency and hyperglycemia. Glucagon-like peptide-1 (GLP-1) is a gut hormone which secreted by enteroendocrine cell. It has been well documented that GLP-1 could regulate β cell growth and increase insulin secretion to maintain glucose homeostasis. Therefore, our aim was to screen and select lactic acid bacteria (LAB) with abilities to stimulate intestinal GLP-1 secretion. The murine enteroendocrine STC-1 cells were co-cultured with sixty LABs at a ratio of 1: 100 and GLP-1 productions in supernatant were measured. We selected and identified top two strains, Lactobacillus kefiranofaciens and Lactobacillus kefiri, significantly elevating GLP-1 secretion when compared with control group (p< 0.05). We next investigated GLP-1 secretion abilities and improvement of hyperglycemia in vivo. Four-week-old male C57BL/6 mice were induced diabetes by intraperitoneal injection of streptozotocin(STZ) for 4 consecutive days. Diabetic mice were randomly assigned to different groups and were administered PBS or selected two strains 108 CFU per mouse daily for eight weeks. The results exhibited that Lb. kefiranofaciens and Lb. kefiri could significantly lower fasting blood glucose than STZ group after eight week administration. Lb. kefiri also significantly improve glucose homeostasis after oral glucose challenge when compared with the STZ group. We found that Lb. kefiranofaciens and Lb. kefiri group showed significantly higher insulin/pancreas ratio by pancreas immunohistochemistry staining. Modulation effects on cytokines level and an elevation of serum GLP-1 levels were also observed. However, administration of Lb. kefiri did not show significant effect to delay the onset of diabetes in non obese diabetic (NOD) mice. We further tried to address possible mechanism and found that toll-like receptor 2 and short chain fatty acid production might be not involved in blood glucose lowering effect. Taken together, our present study concluded that Lb. kefiranofaciens and Lb. kefiri could stimulate GLP-1 secretion both in vitro and in vivo. Oral administration of Lb. kefiranofaciens and Lb. kefiri provided a benefit to blood glucose homeostasis in STZ-induced T1D model. It suggested that the selected strains might be a potential therapeutic supplementation to T1D. However, the mechanisms need more clarification.

Topic Category 生物資源暨農學院 > 動物科學技術學研究所
生物農學 > 動物學
Reference
  1. 林佑哲。2012。豬肝酵素水解物抑制飲食誘導肥胖大鼠採食量與體增重之研究。國立中興大學農業資源學院動物科學研究所。碩士論文。
    連結:
  2. 陳希嘉。2009。藉由變性梯度膠體電泳及寡核苷酸微陣列技術鑑定乳酸菌之研究。國立臺灣大學生物資源暨農學院動物科學技術學研究所。博士論文。
    連結:
  3. 陳彥伯。2013。克弗爾分離菌株Lactobacillus kefiranofaciens M1對腸道功能調節之影響與機制探討。國立臺灣大學生物資源暨農學院動物科學技術學研究所。博士論文。
    連結:
  4. Akira, S. and K. Takeda. 2004. Toll-like receptor signaling. Immunol. Rev. 4: 499-511.
    連結:
  5. Alam, C., E. Bittoun, D. Bhagwat, S. Valkonen, A. Saari, U. Jaakkola, E. Eerola, P. Huovinen and A. Hanninen. 2011. Effects of a germ-free environment on gut immune regulation and diabetes progression in non-obese diabetic (NOD) mice. Diabetologia 54: 1398-1406.
    連結:
  6. Anderson M. S. and J. A. Bluestone. 2005. THE NOD MOUSE: A model of immune dysregulation. Annu. Rev. Immunol. 23: 447-485.
    連結:
  7. Andriambeloson, E., C. Baillet, P. A. Vitte, G. Garotta, M. Dreano and N. Callizot. 2006. Interleukin-6 attenuates the development of experimental diabetes-related neuropathy. Neuropathology 26: 32-42.
    連結:
  8. Aras, M. A., K. A. Hartnett and E. Aizenman. 2008. Assessment of cell viability in primary neuronal cultures. Curr. Protoc. Neurosci. S44: 7.18.1-7.18.15.
    連結:
  9. Assan, R., G. Feutren, M. Debray-Sachs, M. C. Quiniou-Debrie, C. Laborie, G. Thomas, L. Chatenoud and J. F. Bach. 1985. Metabolic and immunological effects of cyclosporin in recently diagnosed type 1 diabetes mellitus. Lancet 1: 67-71.
    連結:
  10. Bach, J. F. 2002. The effect of infections on susceptibility to autoimmune and allergic diseases. N. Engl. J. Med. 347: 911-920.
    連結:
  11. Belle, T. L. V., K. T. Coppieters and M. G. V. Herrath. 2011. Typ1 1 diabetes: etiology, immunology, and therapeutic strategies. Physiol. Rev. 91: 79-118.
    連結:
  12. Bogunovic, M., S. H. Dave, J. S. Tilstra, D. T. W. Chang, N. Harpaz, H. Xiong, L. F. Mayer and S. E. Plevy. 2007. Enteroendocrine cells express functional Toll-like receptors. Am. J. Physiol. Gastrointest. Liver Physiol. 292: G1770-G1783.
    連結:
  13. Bodansky, H. J., A. Staines, C. Stephenson, D. Haigh and R. Cartwright. 1992. Evidence for an environmental effect in the aetiology of insulin dependent diabetes in a transmigratory population. Br. Med. J. 304: 1020-1022.
    連結:
  14. Bradford, M. M. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72: 248-254.
    連結:
  15. Bronte, V. and M. J. Pittet. 2013. The spleen in local and systemic regulation of immunity. Immunity 39: 806-818.
    連結:
  16. Burcelin, R. 2005. The incretins: a link between nutrients and well-being. Br. J. Nutr. 93. Suppl. 1: S147–S156.
    連結:
  17. Calcinaro, F., S. Dionisi, M. Marinaro, P. Candeloro, V. Bonato, S. Marzotti, R. B. Corneli, E. Ferretti, A. Gulino, F. Grasso, C. De Simone, U. Di Mario, A. Falorni, M. Boirivant and F. Dotta. 2005. Oral probiotic administration induces interleukin-10 production and prevents spontaneous autoimmune diabetes in the non-obese diabetic mouse. Diabetologia 48: 1565-1575.
    連結:
  18. Cani, P. D., A. Everard and T. Duparc. 2013. Gut microbiota, enteroendocrine functions and metabolism. Curr. Opin. Pharmacol. 13: 935–940.
    連結:
  19. Carasi, P., N. M. Ambrosis, G. L. de Antoni, P. Bressollier, M. C. Urdaci and M. de L. A. Serradell. 2014. Adhesion properties of potentially probiotic Lactobacillus kefiri to gastrointestinal mucus. J. Dairy Res. 81: 16-23.
    連結:
  20. Chen, Y. P. and M. J. Chen. 2013. Effects of Lactobacillus kefiranofaciens M1 isolated from kefir grains on germ-free mice. PLoS ONE 8: e78789.
    連結:
  21. Chen, Y. P., P. J. Hsiao, W. S. Hong, T. Y. Dai and M. J. Chen. 2012. Lactobacillus kefiranofaciens M1 isolated from milk kefir grains ameliorates experimental colitis in vitro and in vivo. J. Dairy Sci. 95: 63-74.
    連結:
  22. Chen, Y. P., T. Y. Lee, W. S. Hong, H. H. Hsieh and M. J. Chen. 2013. Effects of Lactobacillus kefiranofaciens M1 isolated from kefir grains on enterohemorrhagic Escherichia coli infection using mouse and intestinal cell models. J. Dairy Sci. 96: 7467–7477.
    連結:
  23. Chervonsky, A. V. 2010. Influence of microbial environment on autoimmunity. Nat. Immunol. 11: 28-35.
    連結:
  24. Choquet-Kastylevsky, G., R. Tedone, M. T. Ducluzeau, J. Kehren, J. F. Nicolas and J. Descotes. 2000. The popliteal lymph node response to streptozotocin is under type 1, MHC class-I restricted, CD8(+) T-cell control. Toxicology 146: 73-82.
    連結:
  25. Cnop, M., N. Welsh, J. C. Jonas, A. Jorns, S. Lenzen and D. L. Eizirik. 2005. Mechanisms of pancreatic β cell death in type 1 and type 2 diabetes. Diabetes 54: S97-S107.
    連結:
  26. de Goffau, M. C., K. Luopajarvi, M. Knip, J. Ilonen, T. Ruohtula, T. Harkonen, L. Orivuori, S. Hakala, G. W. Welling, H. J. Harmsen and O. Vaarala. 2013. Fecal microbiota composition differs between children with β-cell autoimmunity and those without. Diabetes 62: 1238-1244.
    連結:
  27. Donath, M. Y. and S. E. Shoelson. 2011. Type 2 diabetes as an inflammatory disease. Nat. Rev. Immunol. 11: 98-107.
    連結:
  28. Dorman, J. S. and C. H. Bunker. 2000. HLA-DQ locus of the human leukocyte antigen complex and type 1 diabetes mellitus: A HuGE review. Epidemiol. Rev. 22: 218-227.
    連結:
  29. Drucker, D. J. 2006. The biology of incretin hormones. Cell Metab. 3: 153–165.
    連結:
  30. Engelbrektson, A., J. R. Korzenik, A. Pittler, Mary E. Sanders, T. R. Klaenhammer, G. Leyer and C. L. Kitts. 2009. Probiotics to minimize the disruption of faecalmicrobiota in healthy subjects undergoing antibiotic therapy. J. Med. Microbiol. 58: 663-670.
    連結:
  31. Ejtahed, H. S., J. Mohtadi-Nia, A. Homayouni-Rad, M. Niafar, M. Asghari-Jafarabadi and V. Mofid. 2012. Probiotic yogurt improves antioxidant status in type 2 diabetic patients. Nutrition 28: 539-543.
    連結:
  32. Everard, A., V. Lazarevic, M. Derrien, M. Girard, G. G. Muccioli, A. M. Neyrinck, S. Possemiers, A. V. Holle, P. Francois, W. M. de Vos, N. M. Delzenne, J. Schrenzel and P. D. Cani. 2011. Responses of gut microbiota and glucose and lipid metabolism to prebiotics in genetic obese and diet-induced leptin-resistant mice. Diabetes 60: 2775-2786.
    連結:
  33. Ezcurra, M., F. Reimann, F. M. Gribble and E. Emery. 2013. Molecular mechanisms of incretin hormone secretion. Curr. Opin. Pharmacol. 13: 922-927.
    連結:
  34. Freeland, K. R., and T. M. S. Wolever. 2010. Acute effects of intravenous and rectal acetate on glucagon-like peptide-1, peptide YY, ghrelin, adiponectin and tumour necrosis factor-alpha. Br. J. Nutr.103: 460-466.
    連結:
  35. Freeland, K. R., C. Wilson and T. M. S. Wolever. 2010. Adaptation of colonic fermentation and glucagon-like peptide-1 secretion with increased wheat fibre intake for 1 year in hyperinsulinaemic human subjects. Br. J. Nutr. 103: 82-90.
    連結:
  36. Fujisawa, T., S. Adachi, T. Toba, K. Arihara and T. Mitsuoka. 1988. Lactobacillus kefiranofaciens sp. nov. isolated from kefir grains. Int. J. Syst. Bacteriol. 38: 12-14.
    連結:
  37. Geraedts, M. C. P., F. J. Troost, M. A. J. G. Fischer, L. Edens and W. H. M. Saris. 2011. Direct induction of CCK and GLP-1 release from murine endocrine cells by intact dietary proteins. Mol. Nutr. Food Res. 55: 476-484.
    連結:
  38. Graham, S., P. Courtois, W. J. Malaisse, J. Rozing, F. W. Scott and A. M. I. Mowat. 2004. Enteropathy precedes type 1 diabetes in the BB rat. Gut 53: 1437-1444.
    連結:
  39. Gerritsen, J., H. Smidt, G. T. Rijkers and W. M. de Vos. 2011. Intestinal microbiota in human health and disease: the impact of probiotics. Genes Nutr. 6: 209-240.
    連結:
  40. Guo, X., X. Xia, R. Tang, J. Zhou, H. Zhao and K. Wang. 2008. Development of a real-time PCR method for Firmicutes and Bacteroidetes in faeces and its application to quantify intestinal population of obese and lean pigs. Lett. Appl. Microbiol. 47: 367-373.
    連結:
  41. Herold, K. C., S. E. Gitelman, U. Masharani, W. Hagopian, B. Bisikirska, D. Donaldson, K. Rother, B. Diamond, D. M. Harlan, and J. A. Bluestone. 2005. A single course of anti-CD3 monoclonal antibody hOKT31 (Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 54: 1763-1769.
    連結:
  42. Huan, Y. and K. K. Wu. 2008. Streptozotocin-induced diabetic models in mice and rats. Curr. Protoc. Pharmacol. 40: 5.47.1-5.47.14.
    連結:
  43. International Diabetes Federation. 2013. IDF Diabetes Atlas, 6th edition. Brussels, Belgium: International Diabetes Federation.
    連結:
  44. Johnson, J. D., D. S. Luciani. 2010. Mechanisms of pancreatic beta-cell apoptosis in diabetes and its therapies. Adv. Exp. Med. Biol. 654: 447-462.
    連結:
  45. Kaji, I., S. I. Karaki, and A. Kuwahara. 2014. Short chain fatty acid receptor and its contribution to glucagon-like peptide-1 release. Digestion 89: 31-36.
    連結:
  46. Kandler, O. and P. Kunath. 1983. Lactobacillus kefir sp. nov., a component of the microflora of kefir. Syst. Appl. Microbiol. 4: 286-94.
    連結:
  47. Kielgast, U., J. J. Holst and S. Madsbad. 2011. Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual β-Cell function. Diabetes 60: 1599-1607.
    連結:
  48. Meng, G., M. Rutz, M. Schiemann, J. Metzger, A Grabiec, R. Schwandner, P. B. Luppa, F. Ebel, D. H. Busch, S. Bauer, H. Wagner and C. J. Kirschning. 2004. Antagonistic antibody prevents toll-like receptor 2–driven lethal shock-like syndromes. J. Clin. Invest. 113: 1473-1481.
    連結:
  49. Moon, J. Y., K. H. Jeong, T. W. Lee, C. G. Ihm, S. J. Lim and S. H. Lee. Aberrant recruitment and activation of T cells in diabetic nephropathy. 2012. Am. J. Nephrol. 35: 164-174.
    連結:
  50. Leto, D., and A. R. Saltiel. 2012. Regulation of glucose transport by insulin: traffic control of GLUT4. Nat. Rev. Mol. Cell Bio. 13: 383-396.
    連結:
  51. Li, Y., T. Hansotia, B. Yusta, F. Ris, P. A. Halban and D. J. Drucker. 2003. Glucagon-like peptide-1 receptor signaling modulates β cell apoptosis. J. Biol. Chem. 278: 471-478.
    連結:
  52. Lim, G. E. and P. L. Brubaker. 2006. Glucagon-like peptide 1 secretion by the L-cell. Diabetes 55: S70-S77.
    連結:
  53. Lin, H. V., A. Frassetto, E. J. Kowalik, A. R. Nawrocki, M. M. Lu, J. R. Kosinski, J. A. Hubert, D. Szeto, X. Yao, G. Forrest and D. J. Marsh. 2012. Butyrate and propionate protect against diet-induced obesity and regulate gut hormones via free fatty acid receptor 3-independent mechanisms. PLoS ONE. 7: e35240.
    連結:
  54. Lin, C. Y., C. S. Huang, C. Y. Huang and M. C. Yin. 2009. Anticoagulatory, anti-inflammatory, and antioxidative effects of protocatechuic acid in diabetic mice. J. Agric. Food Chem. 57: 6661-6667.
    連結:
  55. Liu, H., J. Zhang, S. Zhang, F. Yang, P. A. Thacker, G. Zhang, S. Qiao, and X. Ma. 2014. Oral administration of Lactobacillus fermentum I5007 favors intestinal development and alters the intestinal microbiota in formula-fed piglets. J. Agric. Food Chem. 62: 860-866.
    連結:
  56. Liong, M. T. and N. P. Shah. 2005. Acid and bile tolerance and cholesterol removal ability of lactobacilli strains. J. Dairy Sci. 88: 55-66.
    連結:
  57. Lopes, P., A. Fuhrmann, J. Sereno, M.J. Pereira, P. Nunes, J. Pedro, A. Melao, F. Reis and E. Carvalho. 2013. Effects of cyclosporine and sirolimus on insulin-stimulated glucose transport and glucose tolerance in a rat model. Transplant Proc. 45: 1142-1148.
    連結:
  58. Malik, F. S. and C. E. Taplin. 2014. Insulin therapy in children and adolescents with type 1 diabetes. Paediatr. Drugs. 16: 141-150.
    連結:
  59. Mathis, D. and C. Beniost. 2012. The influences of the microbiota on type 1 diabetes: on the threshold of a leap forward in our understanding. Immunol. Rev. 245: 239-249.
    連結:
  60. Meimandipour, A., M. Shuhaimi, A. F. Soleimani, K. Azhar, M. Hair-Bejo, B. M. Kabeir, A. Javanmard, O. M. Anas and A. M. Yazid. 2010. Selected microbial groups and short-chain fatty acids profile in a simulated chicken cecum supplemented with two strains of Lactobacillus. Poult. Sci. 89: 470-476.
    連結:
  61. Melmed, S., K. S. Polonsky, P. R. Larsen and H. M. Kronenberg. 2011. Williams Textbook of Endocrinology, 12th edition. Philadelphia, Saunders/Elsevier.
    連結:
  62. Muller, A., P. Schott-Ohly, C. Dohle and H. Gleichmann. 2002. Differential regulation of Th1-type and Th2-type cytokine profiles in pancreatic islets of C57BL/6 and BALB/c mice by multiple low doses of streptozotocin. Immunobiol. 205: 35-50.
    連結:
  63. Neu, J., C. M. Reverte, A. D. Mackey, K. Liboni, L. M. Tuhacek-Tenace, M. Hatch, N. Li, R. A. Caicedo, D. A. Schatz and M. Atkinson. 2005. Changes in intestinal morphology and permeability in the biobreeding rat before the onset of type 1 diabetes. J. Pediatr. Gastroenterol. Nutr. 40: 589-595.
    連結:
  64. Olson, B. J. S. C. and J. Markwell. 2007. Assays for determination of protein concentration. Curr. Protoc. Protein Sci. 3.4.1-3.4.29.
    連結:
  65. Pancreatic islet transplantation. 2013. NIH publication. No. 13-4693.
    連結:
  66. Petersen, J. S., K. O. Kyvik, P. J. Bingley, E. A. Gale, A. Green, T. Dyrberg and H. Beck-Nielsen. 1997. Population based study of prevalence of islet cell autoantibodies in monozygotic and dizygotic Danish twin pairs with insulin dependent diabetes mellitus. Br. Med. J. 314: 1575-1579.
    連結:
  67. Punaro, G. R., F. R. Maciel, A. M. Rodrigues, M. M. Rogero, C. S. B. Bogsan, M. N. Oliveira, S. S. M. Ihara, S. R. R. Araujo, T. R. C. Sanches, L. C. Andrade and E. M. S. Higa. 2014. Kefir administration reduced progression of renal injury in STZ-diabetic rats by lowering oxidative stress. Nitric Oxide. 37: 53-60.
    連結:
  68. Reid, G. J. A. Younes, H. C. V. der Mei, G. B. Gloor, R. Knight and H. J. Busscher. 2011. Microbiota restoration: natural and supplemented recovery of human microbial communities. Nat. Rev. Microbiol. 9: 27-38.
    連結:
  69. Roep, B. O. and M. Peakman. 2012. Antigen targets of type 1 diabetes autoimmunity. Cold Spring Harb Perspect Med. 2:a007781
    連結:
  70. Roesch, L. F., G. L. Lorca1, G. Casella, A. Giongo, A. Naranjo, A. M. Pionzio, N. Li, V. Mai, C. H. Wasserfall, D. Schatz, M. A. Atkinson, J. Neu and E. W. Triplett. 2009. Culture-independent identification of gut bacteria correlated with the onset of diabetes in a rat model. ISME J. 3: 536-548.
    連結:
  71. Sander, M. E. Impact of probiotics on colonizing microbiota of the gut. 2011. J. Clin. Gastroenterol. 45: S115-S119.
    連結:
  72. Santos, R. R. J., A. Sartori, D. S. Lima, P. R. M. Souza, A. A. M. Coelho-Castelo, V. L. D. Bonato and C. L. Silva. 2009. DNA vaccine containing the mycobacterial hsp65 gene prevented insulitis in MLD-STZ diabetes. J. Immune Based Ther. Vac. 7: 4. doi:10.1186/1476-8518-7-4.
    連結:
  73. Sartor, R. B. 2008. Microbial influences in inflammatory bowel diseases. Gastroenterology 134: 577-594.
    連結:
  74. Schuit, F. C., P. Huypens, H. Heimberg and D. G. Pipeleers. 2001. Glucose sensing in pancreatic β-cells: a model for the study of other glucose-regulated cells in gut, pancreas, and hypothalamus. Diabetes 50: 1-11.
    連結:
  75. Shapiro, A. J., J. R. T. Lakey, E. A. Ryan, G. S. Korbutt, E. Toth, G. L. Warnock, N. M. Kneteman, and R. V. Rajotte. 2000. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N. Engl. J. Med. 343: 230-238.
    連結:
  76. Song, M. Y., E. K. Kim, W. S. Moon, J. W. Park, H. J. Kim, H. S. So, R. Park, K. B. Kwon and B. H. Park. 2009. Sulforaphane protects against cytokine- and streptozotocin-induced β-cell damage by suppressing the NF-κB pathway. Toxicol. Appl. Pharm. 235: 57-67.
    連結:
  77. Staines, A., S. Hanif, S. Ahmed, P. A. McKinney, S. Shera, and H. J. Bodansky. 1997. Incidence of insulin dependent diabetes mellitus in Karachi, Pakistan. Arch. Dis. Child. 76: 121-123.
    連結:
  78. Suen, C. S., and P. Burn. 2012. The potential of incretin-based therapies in type 1 diabetes. Drug Discov. Today. 17: 89-95.
    連結:
  79. Tabuchi, M., M. Ozaki, A. Tamura, N. Yamada, T. Ishida, M. Hosoda and A. Hosono. 2003. Antidiabetic effect of Lactobacillus GG in streptozotocin-induced diabetic rats. Biosci. Biotechnol. Biochem. 67: 1421-1424.
    連結:
  80. Toba, T., S. Abe, K. Arihara and S. Adachi. 1986. A medium for the isolation of capsular bacteria from kefir grains. Agric. Biol. Chem. 50:2673-2674.
    連結:
  81. Tolhurst, G., H. Heffron, Y. S. Lam, H. E. Parker, A. M. Habib, E. Diakogiannaki, J. Cameron, J. Grosse, F. Reimann, and F. M. Gribble. 2012. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes 61: 364–371.
    連結:
  82. Vaarala, O. 2011. The gut as a regulator of early inflammation in type 1 diabetes. Curr. Opin. Endocrinol. Diabetes Obes. 18: 241-247.
    連結:
  83. van Zanten, G. C., A. Knudsen, H. Roytio, S. Forssten, M. Lawther, A. Blennow, S. J. Lahtinen, M. Jakobsen, B. Svensson and L. Jespersen. 2012. The effect of selected synbiotics on microbial composition and short-chain fatty acid production in a model system of the human colon. PLoS ONE. 7: e47212.
    連結:
  84. Verge, C. F., R. Gianani, L. Yu, M. Pietropaolo, T. Smith, R. A. Jackson, J. S. Soeldner and G. S. Eisenbarth. 1995. Late progression to diabetes and evidence for chronic beta-cell autoimmunity in identical twins of patients with type I diabetes. Diabetes 44: 1176-9.
    連結:
  85. von Herrath, M. and M. M. Martinic. 2008. Real-time imaging of the pancreas during development of diabetes. Immunol. Rev. 221: 200-213.
    連結:
  86. von Herrath, M., S. Sanda and K. Herold. 2007. Type 1 diabetes as a relapsing-remitting disease? Nat. Rev. Immunol. 7: 988-994.
    連結:
  87. Voortman, T., H. F. J. Hendriks, R. F. Witkamp and H. M. Wortelboer. 2012. Effects of long- and short-chain fatty acids on the release of gastrointestinal hormones using an ex vivo porcine intestinal tissue model. J. Agric. Food Chem. 60: 9035-9042.
    連結:
  88. Wang, Q., L. Li, E. Xu, V. Wong, C. Rhodes and P. L. Brubaker. 2004. Glucagon-like peptide-1 regulates proliferation and apoptosis via activation of protein kinase B in pancreatic INS-1 beta cells. Diabetologia 47: 478-487.
    連結:
  89. Wang, Z. and H. Gleichmann. 1998. Crucial target molecule in diabetes induced with multiple low doses of streptozotocin in mice. Diabetes 47: 50-56.
    連結:
  90. Watts, T., I. Berti, A. Sapone, T. Gerarduzzi, T. Not, R. Zielke, and A. Fasano. 2005. Role of the intestinal tight junction modulator zonulin in the pathogenesis of type I diabetes in BB diabetic-prone rats. Proc. Natl. Acad. Sci. 102: 2916-2921.
    連結:
  91. Wong, J. M. W., R. de Souza, C. W. C. Kendall, A. Emam and D. J. A. Jenkins. 2006. Colonic health: fermentation and short chain fatty acid. J. Clin. Gastroenterol. 40: 235-243.
    連結:
  92. Wu, K. K. and Y. Huan. 2008. Streptozocin-induced diabetic models in mice and rats. Curr. Protoc. Pharmacol. 5.47.1-5.47.14.
    連結:
  93. Yadav, H., J. H. Lee, J. Lloyd, P. Walter and S. G. Rane. 2013. Beneficial metabolic effects of a probiotic via butyrate-induced GLP-1 hormone secretion. J. Biol. Chem. 288: 25088–25097.
    連結:
  94. Yadav, H., S. Jain and P. R. Sinha. 2007. Antidiabetic effect of probiotic dahi containing Lactobacillus acidophilus and Lactobacillus casei in high fructose fed rats. Nutrition. 23: 62-68.
    連結:
  95. Yadav, H., S. Jain and P. R. Sinha. 2008. The effect of probiotic dahi containing Lactobacillus acidophilus and Lactobacillus casei on gastropathic consequences in diabetic rats. J. Med. Food. 11: 62-68.
    連結:
  96. Yang, N., N. M. Isbe, D. J. Nikolic-Paterson, Y. Li, R. Ye, R. C. Atkins and H. Y. Lan. 1998. Local macrophage proliferation in human glomerulonephritis. Kidney Int. 54: 143-151.
    連結:
  97. Zhang, J., Y. Tokui, K. Yamagata, J. Kozawa, K. Sayama, H. Iwahashi, K. Okita, M. Miuchi, H. Konya, T. Hamaguchi, M. Namba, I. Shimomura and J-i. Miyagawa. 2007. Continuous stimulation of human glucagon-like peptide-1 (7–36) amide in a mouse model (NOD) delays onset of autoimmune type 1 diabetes. Diabetologia 50: 1900-1909.
    連結:
  98. Zhao, G., M. Nyman and J. A. Josson. 2006. Rapid determination of short chain fatty acids in colonic contents and faeces of humans and rats by acidified water-extration and direct-injection gas chromatography. Biomed. Chromatogr. 20: 674-682.
    連結:
  99. 謝馨慧。2011。糖液克弗爾粒於不同發酵基質中之菌相分布與其分離菌株抗腸炎機能性之研究。國立臺灣大學生物資源暨農學院動物科學技術學研究所。碩士論文。
  100. Giongo, A., K. A. Gano, D. B. Crabb, N. Mukherjee, L. L. Novelo, G. Casella, J. C Drew, J. Ilonen, M. Knip, H. Hyoty, R. Veijola, T. Simell, O. Simell, J. Neu, C. H. Wasserfall, D. Schatz, M. A. Atkinson and E. W. Triplett. 2011. Toward defining the autoimmune microbiome for type 1 diabetes. ISME J. 5: 82-91.
  101. Hadisaputro, S., R. R. J. Djokomoeljanto, Judiono and M. H. N. E. Soesatyo. 2012. The effects of oral plain kefir supplementation on proinflammatory cytokine properties of the hyperglycemia wistar rats induced by streptozotocin. Indones. J. Intern. Med. 44: 100-104.
  102. Herold, K. C., W. Hagopian, J. A. Auger, E. Poumian-Ruiz, L. Taylor, D. Donaldson, S. E. Gitelman, D. M. Harlan, D. Xu, R. A. Zivin and J. A. Bluestone. 2002. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N. Engl. J. Med. 346: 1692-1698.
  103. Kumar, V., A. K. Abbas, N. Fausto and R. Mitchell. 2008. Robbins Basic Pathology, 8th edition. Philadelphia, Saunders/Elsevier.
  104. Leiter, E. H., M. Prochazka and D. L. Coleman. 1987. ANIMAL MODEL OF HUMAN DISEASE: The non obese diabetic (NOD) mice. Am. J. Pathol. 128: 380-383.
  105. Murphy K., P. Travers and M. Walport. 2009. Janeway's Immunobiology, 7th Edition. Garland Science, Taylor and Francis Group, LLC.
  106. Ryan, E. A., B. W. Paty, P. A. Senior, D. Bigam, E. Alfadhli, N. M. Kneteman, J. R. T. Lakey and A. M. J. Shapiro. 2005. Five-year follow-up after clinical islet transplantation. Diabetes 54: 2060-2069.
  107. Sapone, A., L. De Magistris, M. Pietzak, M. G. Clemente, A. Tripathi, F. Cucca, R. Lampis, D. Kryszak, M. Carteni, M. Generoso, D. Iafusco, F. Prisco, F. Laghi, G. Riegler, R. Carratu, D. Counts and A. Fasano. 2006. Zonulin upregulation is associated with increased gut permeability in subjects with type 1 diabetes and their relatives. Diabetes 55: 1443-1449.
  108. Tilg, H., E. Trehu, M. B. Atkins, C. A. Dinarello and J. W. Mier. 1994. Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood 83: 113-118.
  109. Turnbaugh, P. J., R. E. Ley, M. Hamady, C. Fraser-Liggett, R. Knight and J. I. Gordon. 2007. The human microbiome project: exploring the microbial part of ourselves in a changing world. Nature 449: 804-810.
  110. Valladares, R., D. Sankar, N. Li, E. Williams, K. K. Lai, A. S. Abdelgeliel, C. F. Gonzalez, C. H. Wasserfall, J. Larkin, D. Schatz, M. A. Atkinson, E. W. Triplett, J. Neu and Lorca, G. L. 2010. Lactobacillus johnsonii N6. 2 mitigates the development of type 1 diabetes in BB-DP rats. PLoS One. 5: e10507.
  111. Ventura-Sobrevilla, J., V. D. Boone-Villa, C. N. Aguilar, R. Roman-Ramos, E. Vega-Avila, E. Campos-Sepulveda and F. Alarcon-Aguilar. 2011. Effect of varying dose and administration of streptozotocin on blood sugar in male CD1 mice. Proc. West. Pharmacol. Soc. 54: 5-9.
  112. Wen, L., R. E. Ley, P. Y. Volchkov, P. B. Stranges, L. Avanesyan, A. C. Stonebraker, C. Hu, F. S. Wong, G. L. Szot, J. A. Bluestone, J. I. Gordon and A. V. Chervonsky. 2008. Innate immunity and intestinal microbiota in the development of type 1 diabetes. Nature 455: 1109-1113.
Times Cited
  1. 黃舜瑜(2017)。探討Lactobacillus kefiri K影響第一型糖尿病之可能機制。臺灣大學動物科學技術學研究所學位論文。2017。1-94。 
  2. 洪偉庭(2015)。探討Lactobacillus mali改善腸炎疾病之功效。臺灣大學動物科學技術學研究所學位論文。2015。1-84。